Phase-I trial of survivin inhibition with EZN-3042 in dogs with spontaneous lymphoma
Abstract Background Lymphoma is a common cancer in dogs. While most dogs receiving chemotherapy experience remission, very few are cured, and median survival times are generally in the 12-month range. Novel approaches to treatment are unquestionably needed. The Inhibitor of Apoptosis Protein (IAP) f...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-03-01
|
| Series: | BMC Veterinary Research |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12917-020-02317-3 |